Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Willke

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Health Economics|May 1, 1997
Confidence intervals for cost-effectiveness ratios: a comparison of four methodsD Polsky, H A Glick, R Willke, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 24, 1999
Towards a composite scoring solution for the Neurobehavioral Functioning InventoryK P Weinfurt, R Willke, H A Glick, et al.
International Journal of Technology Assessment in Health Care|March 24, 1998
Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. Economic evaluation of a phase III clinical trial in Europe and AustraliaH Glick, R Willke, D Polsky, et al.
Health Economics|December 9, 1998
Resource costing for multinational neurologic clinical trials: methods and resultsK Schulman, J Burke, M Drummond, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Health Economics|May 1, 1997
Confidence intervals for cost-effectiveness ratios: a comparison of four methodsD Polsky, H A Glick, R Willke, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 24, 1999
Towards a composite scoring solution for the Neurobehavioral Functioning InventoryK P Weinfurt, R Willke, H A Glick, et al.
International Journal of Technology Assessment in Health Care|March 24, 1998
Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. Economic evaluation of a phase III clinical trial in Europe and AustraliaH Glick, R Willke, D Polsky, et al.
Health Economics|December 9, 1998
Resource costing for multinational neurologic clinical trials: methods and resultsK Schulman, J Burke, M Drummond, et al.
Pageof 1